Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IONS

Ionis Pharmaceuticals Inc

Nov 03 • 04:00PM ET

73.65

-0.65 -0.87 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN VRTX GILD NBIX ALNY PRTA ARWR SRPT FOLD

| Held by: VTI VB VBK XBI VXF IWP IBB SCHA ARKG IWF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.71	Insider Own	0.75%	Shs Outstand	161.14M	Perf Week	0.90%
Market Cap	11.93B	Forward P/E	-	EPS next Y	-3.19	Insider Trans	-47.24%	Shs Float	160.75M	Perf Month	6.51%
Enterprise Value	11.73B	PEG	-	EPS next Q	-1.33	Inst Own	105.38%	Short Float	8.52%	Perf Quarter	71.08%
Income	-255.99M	P/S	12.33	EPS this Y	22.86%	Inst Trans	1.07%	Short Ratio	5.51	Perf Half Y	118.90%
Sales	967.38M	P/B	19.20	EPS next Y	-35.97%	ROA	-8.37%	Short Interest	13.70M	Perf YTD	110.67%
Book/sh	3.84	P/C	5.32	EPS next 5Y	27.73%	ROE	-39.99%	52W High	75.49 -2.44%	Perf Year	87.60%
Cash/sh	13.85	P/FCF	-	EPS past 3/5Y	-146.45% -	ROIC	-12.66%	52W Low	23.95 207.52%	Perf 3Y	69.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-4.53% -8.88%	Gross Margin	97.07%	Volatility	3.41% 2.77%	Perf 5Y	56.77%
Dividend TTM	-	EV/Sales	12.13	EPS Y/Y TTM	34.00%	Oper. Margin	-28.66%	ATR (14)	2.11	Perf 10Y	61.80%
Dividend Ex-Date	-	Quick Ratio	2.78	Sales Y/Y TTM	20.39%	Profit Margin	-26.46%	RSI (14)	66.33	Recom	1.56
Dividend Gr. 3/5Y	- -	Current Ratio	2.79	EPS Q/Q	14.85%	SMA20	2.34%	Beta	0.31	Target Price	82.86
Payout	-	Debt/Eq	3.32	Sales Q/Q	17.12%	SMA50	14.02%	Rel Volume	1.04	Prev Close	74.30
Employees	1069	LT Debt/Eq	2.27	Earnings	Oct 29 BMO	SMA200	73.48%	Avg Volume	2.48M	Price	73.65
IPO	May 17, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	34.33% 20.47%	Trades		Volume	2,576,035	Change	-0.87%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-08-25	Upgrade	JP Morgan	Neutral → Overweight	$80
Sep-26-25	Upgrade	Goldman	Sell → Neutral	$65
Sep-03-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$70
Jul-31-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$62
Jul-01-25	Upgrade	Barclays	Equal Weight → Overweight	$57
Apr-07-25	Initiated	H.C. Wainwright	Buy	$45
Mar-31-25	Initiated	Redburn Atlantic	Neutral	$39
Aug-02-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$67 → $60
Jul-24-24	Upgrade	Leerink Partners	Market Perform → Outperform	$53 → $62
Jul-16-24	Resumed	Jefferies	Buy	$29 → $75
Jun-14-24	Upgrade	Bernstein	Underperform → Mkt Perform	$44
Apr-10-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$58
Jan-02-24	Upgrade	BofA Securities	Neutral → Buy	$52 → $62
Oct-23-23	Upgrade	BofA Securities	Underperform → Neutral	$33 → $52
Sep-29-23	Initiated	Raymond James	Strong Buy	$63
Jul-31-23	Upgrade	Citigroup	Neutral → Buy	$36 → $60
Jun-07-23	Resumed	Piper Sandler	Overweight	$58
May-04-23	Upgrade	Citigroup	Sell → Neutral	$30 → $36
Mar-21-23	Initiated	Bernstein	Underperform	$31
Dec-21-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $40

Show Previous Ratings

Oct-31-25 05:00PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
Oct-30-25 04:15PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
01:14PM	Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook (Zacks)
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
Oct-29-25 09:30AM	Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics (Zacks)
08:15AM	Loading…
08:15AM	Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:14AM	Ionis Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Ionis reports third quarter 2025 financial results and highlights progress on key programs (Business Wire)
Oct-27-25 07:00AM	Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions (Business Wire)
Oct-23-25 02:10PM	Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture (Business Wire)
Oct-22-25 10:00AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-21-25 08:00AM	Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society (Business Wire)
Oct-16-25 07:05AM	Ionis to hold third quarter 2025 financial results webcast (Business Wire)
Oct-08-25 04:14PM	Why Ionis Stock Hit A Six-Year High And Snagged A Price-Target Hike (Investor's Business Daily)
09:45AM	Intel, FedEx downgraded: Wall Street's top analyst calls (The Fly)
09:35AM	Loading…
09:35AM	Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike (Investor's Business Daily)
Oct-07-25 09:26AM	Ionis Pharmaceuticals CEO Brett Monia on the drugs they are focused on (CNBC TV)
07:00AM	Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day (Business Wire)
Oct-02-25 01:35AM	Ionis (IONS) Price Target Hiked Following Positive Zilganersen Trial Results (Insider Monkey)
Sep-30-25 07:08PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
Sep-26-25 09:46AM	CarMax downgraded, Kenvue upgraded: Wall Street's top analyst calls (The Fly)
Sep-24-25 12:41PM	BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL (Zacks)
Sep-23-25 02:15PM	IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal (Zacks)
01:13PM	Biotech Stocks Rally. 3 Favorite Plays From the Charts. (Barrons.com)
04:54AM	FDA clears under-the-skin Keytruda; MBX shares double on study data (BioPharma Dive)
Sep-22-25 07:00AM	Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease (Business Wire)
06:01AM	Ionis and Sobis Tryngolza gains approval in EU for FCS treatment (Pharmaceutical Technology)
Sep-19-25 07:00AM	TRYNGOLZA (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS) (Business Wire)
Sep-18-25 07:07AM	Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs (BioPharma Dive)
Sep-12-25 07:00AM	Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases (Business Wire)
11:11AM	Loading…
Sep-10-25 11:11AM	IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome (Zacks)
Sep-09-25 07:00AM	Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome (Business Wire) +5.57%
Sep-08-25 04:00PM	Ionis to host investors and analysts for Innovation Day 2025 (Business Wire)
Sep-04-25 12:34PM	Ionis Pharma (IONS) Hits New High Anew as Analyst Sees Blockbuster Potential for Olezarsen (Insider Monkey)
Sep-03-25 11:13AM	Ionis Pharma (IONS) Touches New High on Promising Olezarsen Results (Insider Monkey) +5.22%
10:47AM	IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride (Zacks)
08:52AM	Pharma, Opendoor, Tesla: Trending Stocks (Yahoo Finance Video)
Sep-02-25 09:05PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research) +34.84%
06:00PM	More Ways to Cut Cholesterol, Triglycerides Are Coming. This Stock Took Off. (Barrons.com)
04:06PM	Ionis Pharma Hits Four-Year High On A 'Home Run' In Triglycerides Treatment (Investor's Business Daily)
04:00PM	Ionis to present at upcoming investor conferences (Business Wire)
10:38AM	Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction (Benzinga)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
10:01AM	Ionis Pharma Hits The 'Bull Case,' 'Blue Sky' In Lowering Triglycerides. Shares Launch. (Investor's Business Daily)
07:00AM	Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG) (Business Wire)
01:34AM	Ionis Pharmaceuticals (IONS) Gains FDA Approval for HAE Drug, Piper Sandler Lifts Target (Insider Monkey)
Aug-28-25 11:49PM	J.P. Morgan Raises the PT on Ionis Pharmaceuticals (IONS), Keeps a Hold Rating (Insider Monkey)
Aug-21-25 05:49PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
02:24PM	Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder (Benzinga)
11:45AM	DAWNZERA (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema (Business Wire)
Aug-04-25 11:29AM	Why Morgan Stanley Upgraded This Biotech Stock to a Buy (Barchart)
Jul-31-25 01:12PM	BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock (Zacks)
09:10AM	Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook (Zacks)
03:28AM	Ionis Pharmaceuticals Inc (IONS) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
12:16AM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
Jul-30-25 09:30AM	Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings (Zacks)
08:10AM	Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates (Zacks)
07:08AM	Ionis Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ionis reports second quarter 2025 financial results and highlights progress on key programs (Business Wire)
Jul-29-25 01:30AM	Ionis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines Agency (Insider Monkey)
Jul-25-25 07:32AM	TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS) (PR Newswire)
07:15AM	TRYNGOLZA (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS) (Business Wire)
Jul-23-25 10:00AM	Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-21-25 07:00AM	Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice (Business Wire)
Jul-16-25 07:05AM	Ionis to hold second quarter 2025 financial results webcast (Business Wire)
Jul-14-25 04:01AM	Amyotrophic Lateral Sclerosis (ALS) Market Analysis Report 2025-2035 \| Increase in Clinical Trials and Investments will Accelerate the Development of Innovative Treatments (GlobeNewswire)
Jul-10-25 12:39AM	Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT (Insider Monkey)
Jul-03-25 09:55AM	Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross? (Zacks)
08:17AM	Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last? (Zacks)
Jul-02-25 07:11PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research) +9.14%
09:36AM	Nike upgraded, Sportradar initiated: Wall Streets top analyst calls (TipRanks)
Jul-01-25 09:33AM	Nike upgraded, Sportradar initiated: Wall Street's top analyst calls (The Fly)
Jun-27-25 10:00AM	New Data for Nusinersen Underscore Biogens Commitment to Advancing Clinical Research to Improve Outcomes in SMA (GlobeNewswire)
Jun-25-25 04:19PM	Can Biogen Save Even More Kids With This New Drug? (Investor's Business Daily)
07:31AM	Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results (Business Wire)
07:30AM	Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? (Investor's Business Daily)
07:30AM	Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results (GlobeNewswire)
Jun-23-25 01:37AM	First Patient Dosed In Phase 3 REVEAL Study Of ION582 For Angelman Syndrome (Insider Monkey)
Jun-12-25 09:00AM	Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026 (Business Wire)
07:23AM	Ionis doses first subject in Phase III trial of Angelman syndrome therapy (Clinical Trials Arena)
Jun-11-25 07:00AM	First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome (Business Wire)
Jun-05-25 11:30AM	Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report? (Zacks)
Jun-04-25 11:30AM	Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue? (Zacks)
May-30-25 11:31AM	Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report? (Zacks)
May-22-25 12:43PM	Ionis reports success in olezarsen trial for high triglycerides (Clinical Trials Arena)
May-20-25 11:44AM	Ionis reports positive data from study of olezarsen for hypertriglyceridemia (Clinical Trials Arena)
08:58AM	Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study (Zacks)
May-19-25 07:00AM	Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides (Business Wire)
May-11-25 04:40PM	Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin's Stock Picks with Huge Upside Potential (Insider Monkey)
May-06-25 07:05AM	Ionis to host 2025 virtual Annual Meeting of Stockholders (Business Wire) -5.31%
May-02-25 07:25AM	Tweedy, Browne Fund Q1 2025 Commentary (Seeking Alpha)
May-01-25 01:37PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
10:42AM	Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View (Zacks)
09:35AM	ClearBridge Growth Portfolios Q1 2025 Commentary (Seeking Alpha)
09:30AM	ClearBridge Growth ESG Portfolios Q1 2025 Commentary (Seeking Alpha)
03:16AM	Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
02:43AM	Q1 2025 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-30-25 09:35PM	ClearBridge Growth Fund Q1 2025 Commentary (Seeking Alpha)
02:20PM	Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WENDER JOSEPH H	Director	Oct 30 '25	Sale	73.26	16,800	1,230,801	75,235	Nov 03 08:14 PM
WENDER JOSEPH H	Director	Oct 31 '25	Sale	75.16	11,200	841,776	64,035	Nov 03 08:14 PM
LOSCALZO JOSEPH	Director	Oct 31 '25	Option Exercise	52.22	16,000	835,520	52,330	Nov 03 08:14 PM
LOSCALZO JOSEPH	Director	Oct 31 '25	Sale	75.10	16,000	1,201,669	36,330	Nov 03 08:14 PM
Geary Richard S	EVP, Chief Development Officer	Oct 31 '25	Option Exercise	58.83	69,249	4,074,103	114,321	Nov 03 08:14 PM
Geary Richard S	EVP, Chief Development Officer	Nov 03 '25	Option Exercise	58.99	1,680	99,110	60,562	Nov 03 08:14 PM
Geary Richard S	EVP, Chief Development Officer	Oct 31 '25	Sale	75.11	89,249	6,703,341	59,657	Nov 03 08:14 PM
Geary Richard S	EVP, Chief Development Officer	Nov 03 '25	Sale	75.05	1,680	126,091	59,657	Nov 03 08:14 PM
LOSCALZO JOSEPH	Officer	Oct 31 '25	Proposed Sale	75.10	16,000	1,201,669		Oct 31 04:26 PM
Geary Richard S	Officer	Oct 31 '25	Proposed Sale	75.10	126,168	9,475,217		Oct 31 04:25 PM
Joseph Wender	Director	Oct 30 '25	Proposed Sale	74.17	33,600	2,492,112		Oct 30 06:21 PM
Swayze Eric	EVP Research	Oct 15 '25	Option Exercise	0.00	125	0	309	Oct 16 08:16 PM
Swayze Eric	EVP Research	Oct 16 '25	Sale	73.62	53	3,902	256	Oct 16 08:16 PM
PARSHALL B LYNNE	Director	Oct 15 '25	Sale	71.74	5,000	358,722	61,344	Oct 16 08:16 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Oct 15 '25	Option Exercise	33.00	8,820	291,060	21,937	Oct 16 08:16 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Oct 15 '25	Sale	72.94	6,000	437,654	15,937	Oct 16 08:16 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Oct 16 '25	Sale	73.62	1,263	92,984	17,494	Oct 16 08:16 PM
Birchler Brian	EVP, Corp and Development Ops	Oct 15 '25	Option Exercise	53.77	12,425	668,092	69,251	Oct 16 08:15 PM
Birchler Brian	EVP, Corp and Development Ops	Oct 14 '25	Option Exercise	53.77	11,475	617,011	68,301	Oct 16 08:15 PM
Birchler Brian	EVP, Corp and Development Ops	Oct 15 '25	Sale	72.23	12,425	897,398	56,826	Oct 16 08:15 PM
Birchler Brian	EVP, Corp and Development Ops	Oct 14 '25	Sale	72.03	11,475	826,589	56,826	Oct 16 08:15 PM
Devers Shannon L.	Officer	Oct 15 '25	Proposed Sale	75.00	15,670	1,175,250		Oct 15 04:10 PM
PARSHALL B LYNNE	Director	Oct 15 '25	Proposed Sale	71.74	5,000	358,722		Oct 15 04:08 PM
Birchler Brian	Officer	Oct 14 '25	Proposed Sale	72.00	31,900	2,296,800		Oct 14 04:58 PM
Swayze Eric	EVP Research	Oct 06 '25	Sale	69.02	6,849	472,718	30,453	Oct 08 06:37 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Oct 06 '25	Option Exercise	52.87	10,200	539,274	67,330	Oct 08 06:37 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Oct 06 '25	Sale	69.74	13,441	937,338	53,889	Oct 08 06:37 PM
Monia Brett P	Chief Executive Officer	Oct 06 '25	Sale	69.26	437	30,268	179,572	Oct 08 06:36 PM
Baroldi Joseph	EVP, Chief Business Officer	Oct 06 '25	Sale	69.37	1,625	112,725	30,301	Oct 08 06:36 PM
Monia Brett P	Officer	Oct 06 '25	Proposed Sale	69.26	437	30,268		Oct 06 06:24 PM
Baroldi Joseph	Officer	Oct 06 '25	Proposed Sale	69.37	1,625	112,725		Oct 06 06:09 PM
Swayze Eric	Officer	Oct 06 '25	Proposed Sale	69.02	6,849	472,718		Oct 06 06:01 PM
WENDER JOSEPH H	Director	Oct 01 '25	Sale	65.50	16,800	1,100,385	92,035	Oct 02 07:36 PM
Swayze Eric	EVP Research	Oct 01 '25	Option Exercise	53.77	14,142	760,415	51,444	Oct 02 07:36 PM
Swayze Eric	EVP Research	Oct 02 '25	Option Exercise	53.77	12,972	697,504	50,274	Oct 02 07:36 PM
Swayze Eric	EVP Research	Oct 01 '25	Sale	66.09	14,142	934,662	37,302	Oct 02 07:36 PM
Swayze Eric	EVP Research	Oct 02 '25	Sale	66.23	12,972	859,082	37,302	Oct 02 07:36 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Oct 02 '25	Option Exercise	58.97	64,664	3,813,257	91,591	Oct 02 07:35 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Oct 02 '25	Sale	67.69	64,664	4,377,054	57,130	Oct 02 07:35 PM
Baroldi Joseph	EVP, Chief Business Officer	Oct 02 '25	Option Exercise	31.80	15,000	477,000	46,926	Oct 02 07:35 PM
Baroldi Joseph	EVP, Chief Business Officer	Oct 02 '25	Sale	68.01	15,000	1,020,210	31,926	Oct 02 07:35 PM
O'NEIL PATRICK R.	Officer	Oct 02 '25	Proposed Sale	67.69	78,105	5,286,865		Oct 02 06:11 PM
Baroldi Joseph	Officer	Oct 02 '25	Proposed Sale	68.01	15,000	1,020,210		Oct 02 05:43 PM
Joseph Wender	Director	Oct 01 '25	Proposed Sale	65.80	22,400	1,473,920		Oct 01 05:33 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Sep 30 '25	Option Exercise	56.78	14,827	841,877	71,957	Oct 01 04:55 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Sep 29 '25	Option Exercise	56.78	10,473	594,657	67,603	Oct 01 04:55 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Sep 30 '25	Sale	64.68	14,827	958,976	57,130	Oct 01 04:55 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Sep 29 '25	Sale	64.54	10,473	675,945	57,130	Oct 01 04:55 PM
Geary Richard S	EVP, Chief Development Officer	Sep 30 '25	Option Exercise	53.77	57,900	3,113,283	137,557	Oct 01 04:55 PM
Geary Richard S	EVP, Chief Development Officer	Sep 30 '25	Sale	65.24	57,900	3,777,668	79,657	Oct 01 04:55 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Sep 30 '25	Option Exercise	53.77	49,800	2,677,746	160,300	Oct 01 04:55 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Sep 30 '25	Sale	65.26	49,800	3,249,734	110,500	Oct 01 04:55 PM
Swayze Eric	Officer	Oct 01 '25	Proposed Sale	66.00	27,114	1,789,524		Oct 01 04:39 PM
Geary Richard S	Officer	Sep 30 '25	Proposed Sale	65.24	57,900	3,777,668		Sep 30 04:49 PM
HOUGEN ELIZABETH L	Officer	Sep 30 '25	Proposed Sale	65.26	49,800	3,249,734		Sep 30 04:39 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Sep 12 '25	Option Exercise	56.78	1,700	96,526	58,830	Sep 16 04:56 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Sep 12 '25	Sale	64.58	1,700	109,787	57,130	Sep 16 04:56 PM
Baroldi Joseph	EVP, Chief Business Officer	Sep 09 '25	Option Exercise	31.80	11,950	380,010	43,876	Sep 11 05:05 PM
Baroldi Joseph	EVP, Chief Business Officer	Sep 09 '25	Sale	62.16	11,950	742,838	31,926	Sep 11 05:05 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Sep 09 '25	Option Exercise	60.69	21,000	1,274,580	77,130	Sep 11 05:04 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Sep 09 '25	Sale	64.56	21,000	1,355,661	57,130	Sep 11 05:04 PM
Baroldi Joseph	EVP, Chief Business Officer	Sep 05 '25	Option Exercise	31.80	250	7,950	32,176	Sep 09 06:30 PM
Baroldi Joseph	EVP, Chief Business Officer	Sep 05 '25	Sale	62.00	250	15,500	31,926	Sep 09 06:30 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Sep 05 '25	Sale	59.60	6,000	357,581	82,679	Sep 09 06:30 PM
Swayze Eric	EVP Research	Sep 02 '25	Sale	49.67	11,130	552,862	37,302	Sep 04 08:41 PM
WENDER JOSEPH H	Director	Sep 02 '25	Sale	55.87	16,800	938,606	120,035	Sep 04 08:40 PM
WENDER JOSEPH H	Director	Sep 03 '25	Sale	60.14	11,200	673,549	108,835	Sep 04 08:40 PM
PARSHALL B LYNNE	Director	Sep 02 '25	Sale	50.91	20,000	1,018,298	66,344	Sep 04 08:38 PM
Monia Brett P	Chief Executive Officer	Sep 03 '25	Option Exercise	44.32	203,814	9,032,039	308,324	Sep 04 08:38 PM
Monia Brett P	Chief Executive Officer	Sep 03 '25	Sale	60.32	203,814	12,294,703	180,009	Sep 04 08:38 PM
KLEIN JOSEPH III	Director	Sep 03 '25	Option Exercise	0.00	28,000	0	28,000	Sep 04 08:38 PM
KLEIN JOSEPH III	Director	Sep 03 '25	Sale	60.00	28,000	1,680,000	0	Sep 04 08:38 PM
KLEIN JOSEPH III	Director	Sep 03 '25	Option Exercise	0.00	28,000	0	28,000	Sep 04 08:37 PM
KLEIN JOSEPH III	Director	Sep 03 '25	Sale	60.00	28,000	1,680,000	0	Sep 04 08:37 PM
Geary Richard S	EVP, Chief Development Officer	Sep 02 '25	Sale	50.37	10,000	503,671	79,657	Sep 04 08:37 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Sep 03 '25	Option Exercise	36.12	3,162	114,207	18,171	Sep 04 08:36 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Sep 03 '25	Sale	61.02	3,162	192,943	15,009	Sep 04 08:36 PM
WENDER JOSEPH H	Director	Sep 02 '25	Sale	55.87	16,800	938,606	120,035	Sep 04 08:34 PM
WENDER JOSEPH H	Director	Sep 03 '25	Sale	60.14	11,200	673,549	108,835	Sep 04 08:34 PM
Baroldi Joseph	EVP, Chief Business Officer	Sep 03 '25	Option Exercise	31.80	32,800	1,043,040	46,926	Sep 04 08:34 PM
Baroldi Joseph	EVP, Chief Business Officer	Sep 03 '25	Sale	59.34	32,800	1,946,220	16,926	Sep 04 08:34 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Sep 03 '25	Option Exercise	47.23	76,850	3,629,296	71,130	Sep 04 08:29 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Sep 02 '25	Option Exercise	32.60	13,050	425,430	70,180	Sep 04 08:29 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Sep 03 '25	Sale	60.97	76,850	4,685,425	5,655	Sep 04 08:29 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Sep 02 '25	Sale	54.51	13,050	711,418	57,130	Sep 04 08:29 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Sep 03 '25	Option Exercise	53.77	46,800	2,516,436	135,479	Sep 04 08:29 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Sep 03 '25	Sale	60.62	33,909	2,055,564	101,570	Sep 04 08:29 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Sep 02 '25	Sale	49.14	5,000	245,700	88,679	Sep 04 08:29 PM
LOSCALZO JOSEPH	Director	Sep 03 '25	Option Exercise	24.42	16,000	390,720	52,330	Sep 04 08:28 PM
LOSCALZO JOSEPH	Director	Sep 03 '25	Sale	60.15	16,000	962,371	36,330	Sep 04 08:28 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Sep 03 '25	Option Exercise	53.77	19,658	1,057,011	71,165	Sep 04 08:28 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Sep 03 '25	Sale	60.81	19,658	1,195,421	51,507	Sep 04 08:28 PM
LOSCALZO JOSEPH	Officer	Sep 03 '25	Proposed Sale	60.15	16,000	962,371		Sep 03 05:31 PM
O'NEIL PATRICK R.	Officer	Sep 03 '25	Proposed Sale	61.15	124,850	7,634,553		Sep 03 05:15 PM
BENNETT C FRANK	Officer	Sep 03 '25	Proposed Sale	60.86	51,800	3,152,698		Sep 03 04:54 PM
Baroldi Joseph	Officer	Sep 03 '25	Proposed Sale	59.09	45,000	2,658,996		Sep 03 04:37 PM
Monia Brett P	Officer	Sep 03 '25	Proposed Sale	60.01	203,814	12,230,307		Sep 03 04:30 PM
Devers Shannon L.	Officer	Sep 03 '25	Proposed Sale	61.02	3,162	192,958		Sep 03 04:21 PM
Schneider Eugene	Officer	Sep 03 '25	Proposed Sale	60.81	19,658	1,195,421		Sep 03 04:20 PM
Joseph Wender	Director	Sep 02 '25	Proposed Sale	57.49	33,600	1,931,664		Sep 02 08:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IONS

Ionis Pharmaceuticals Inc

Upgrade your FINVIZ experience